Novartis ADR Forecast, price target & analysts
Novartis ADR Target price 2025 - Analyst rating & recommendation
Novartis ADR Classifications & Recommendation:
Novartis ADR Price Target
| Target Price | $137.62 |
| Price | $130.50 |
| Potential |
5.45%
register free of charge
|
| Number of Estimates | 25 |
|
25 Analysts have issued a price target Novartis ADR 2026 .
The average Novartis ADR target price is $137.62.
This is
5.45%
register free of charge
$157.41
20.62%
register free of charge
$100.94
22.65%
register free of charge
|
|
| A rating was issued by 31 analysts: 13 Analysts recommend Novartis ADR to buy, 14 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Novartis ADR stock has an average upside potential 2026 of
5.45%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 51.72 | 56.60 |
| 10.85% | 9.44% | |
| EBITDA Margin | 31.96% | 41.31% |
| 14.24% | 29.27% | |
| Net Margin | 23.09% | 30.96% |
| 27.46% | 34.10% |
24 Analysts have issued a sales forecast Novartis ADR 2025 . The average Novartis ADR sales estimate is
This results in the following potential growth metrics:
18 Analysts have issued an Novartis ADR EBITDA forecast 2025. The average Novartis ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Novartis ADR Analysts have issued a net profit forecast 2025. The average Novartis ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 5.87 | 9.13 |
| 17.21% | 55.54% | |
| P/E | 14.29 | |
| EV/Sales | 4.69 |
25 Analysts have issued a Novartis ADR forecast for earnings per share. The average Novartis ADR EPS is
This results in the following potential growth metrics and future valuations:
Current Novartis ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| GUGGENHEIM SECURITIES LLC |
Locked
➜
Locked
|
Locked | Sep 09 2025 |
| DAY BY DAY |
Locked
➜
Locked
|
Locked | Sep 08 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
| TD COWEN |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| INTESA SANPAOLO EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| LANDESBANK BADEN-WUERTTEMBERG |
Locked
➜
Locked
|
Locked | Jul 23 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
GUGGENHEIM SECURITIES LLC:
Locked
➜
Locked
|
Sep 09 2025 |
|
Locked
DAY BY DAY:
Locked
➜
Locked
|
Sep 08 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 02 2025 |
|
Locked
TD COWEN:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
INTESA SANPAOLO EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
LANDESBANK BADEN-WUERTTEMBERG:
Locked
➜
Locked
|
Jul 23 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
